Purpose:
To estimate the scattered dose to conceptus from involved-field radiotherapy for Hodgkin's lymphoma on a linear accelerator equipped with multileaf collimators.
Material and Methods:
Anthropomorphic phantoms were used to simulate an average pregnant woman at the 1st, 2nd and 3rd trimesters of gestation. Conceptus dose was measured using thermoluminescent dosimeters. Phantom measurements were performed for the minimum, medium and maximum field dimensions that may be employed during radiation therapy to lymph nodes in the neck, axilla, mediastinum and neck-mediastinum. The components of the scattered dose to conceptus were determined. Phantom exposures were generated with a 6-MV photon beam.
Results:
Neck irradiation with a tumor dose of 35 Gy resulted in a conceptus dose of 1.1–8.7 cGy depending upon the stage of pregnancy, the distance from treatment volume, and the field size applied. The corresponding conceptus dose ranges from radiotherapy in the regions of axilla, mediastinum and neck-mediastinum was 1.2–14.3 cGy, 3.7–57.7 cGy, and 5.1–91.8 cGy, respectively. The contribution of collimator scatter and head leakage to the total conceptus dose varied from 21% to 80% depending upon the irradiation site and gestational age.
Conclusion:
The conceptus dose associated with cervical node irradiation is below the threshold value of 10 cGy during the entire pregnancy. Radiation therapy to lymph nodes in the axilla, mediastinum and neck-mediastinum may possibly lead to a conceptus dose of > 10 cGy and, therefore, informed decisions about the pregnancy termination should be made.
Ziel:
Messung der durch Streustrahlung bedingten fetalen Dosis bei Involved-Field-Radiotherapie wegen Hodgkin-Lymphom an einem Linearbeschleuniger mit Multileafkollimatoren (MLC).
Material und Methodik:
An anthropomorphen Phantomen wurde eine durchschnittliche Schwangere im 1., 2. und 3. Trimenon simuliert. Die Dosis im Fetus wurde mit Thermolumineszenzdosimetern gemessen. Die Phantommessungen wurden für die minimalen, mittleren und maximalen Feldgrößen durchgeführt, die bei der Bestrahlung von Lymphknoten in Hals, Axilla, Mediastinum und Hals-Mediastinum verwendet werden können. Der Anteil der Streustrahlendosis im Fetus wurde bestimmt. Die Phantomexposition wurde mit 6-MV-Photonenstrahlung generiert.
Ergebnisse:
Die Bestrahlung des Halses mit einer Tumordosis von 35 Gy führte in Abhängigkeit von Schwangerschaftsstadium, Entfernung vom Behandlungsvolumen und verwendeter Feldgröße zu einer fetalen Dosis von 1,1–8,7 cGy. Die entsprechenden fetalen Dosisbereiche bei Bestrahlung in der Axilla-, Mediastinum- und Hals-Mediastinum-Region betrugen 1,2–14,3 cGy, 3,7–57,7 cGy und 5,1–91,8 cGy. Der Anteil von Kollimatorstreuung und Kopfleckage an der Gesamtdosis, welcher der Fetus ausgesetzt ist, liegt in Abhängigkeit von Tumorsitz und Gestationsalter bei 21–80%.
Schlussfolgerung:
Die fetale Dosis bei Bestrahlung der zervikalen Lymphknoten liegt während der gesamten Schwangerschaft < 10 cGy. Die Bestrahlung von Lymphknoten in Axilla, Mediastinum und Hals-Mediastinum führt möglicherweise zu einer fetalen Dosis > 10 cGy, so dass nach Aufklärung eine Entscheidung hinsichtlich eines Schwangerschaftsabbruchs getroffen werden sollte.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Becker MH, Hyman GA. Management of Hodgkin’s disease coexistent with pregnancy. Radiology 1965;85:725–8.
Buchgeister M, Mondry A, Spillner P, et al. A special radiation shielding for the radiotherapy of a pregnant patient. Strahlenther Onkol 2008;184:80–5.
Conley JG, Jacobson A. Modified radiation therapy regimen for Hodgkin’s disease in the third trimester of pregnancy. Am J Radiol 1977;128:666–7.
Covington EE, Baker AS. Dosimetry of scattered radiation to the fetus. JAMA 1969;209:414–5.
Cygler J, Ding GX, Kendal W, et al. Fetal dose for a patient undergoing mantle field irradiation for Hodgkin’s disease. Med Dosim 1997;22:135–7.
Eich HT, Muller R. Current role and future developments of radiotherapy in early-stage favorable Hodgkin’s lymphoma. Strahlenther Onkol 2007;183:16–8.
Eich HT, Muller RP, Engenhart-Cabillic R, et al. Involved-node radiotherapy in early stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 2008;184:406–10.
Greskovich JF, Macklis RM. Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol 2000;27:633–45.
Hass JF. Pregnancy in association with a newly diagnosed cancer: a population-based epidemiologic assessment. Int J Cancer 1984;34:229–35.
ICRP. International Commission on Radiological Protection, Publication 84. Pregnancy and medical radiation. Oxford: Pergamon Press, 2000.
Jacobs C, Donaldson SS, Rosenberg SA, et al. Management of the pregnant patient with Hodgkin’s disease. Ann Intern Med 1981;95:669–75.
Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 2005;6:328–33.
Khan FM, ed. Treatment planning in radiation oncology, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2007.
Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007;2:1–11.
Kry SF, Titt U, Ponisch F, et al. A Monte Carlo model for calculating out-of-field dose from a Varian 6 MV beam. Med Phys 2006;33:4405–13.
Mazonakis M, Damilakis J, Theoharopoulos N, et al. Brain radiotherapy during pregnancy: an analysis of conceptus dose using anthropomorphic phantoms. Br J Radiol 1999;72:274–8.
Mazonakis M, Varveris H, Fasoulaki M, et al. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol 2003;66:333–9.
Mazonakis M, Zacharopoulou F, Kachris S, et al. Scattered dose to gonads and associated risks from radiotherapy for common pediatric malignancies. A phantom study. Strahlenther Onkol 2007;183:332–7.
Mutic S, Esthappan J, Klein EE. Peripheral dose distributions for a linear accelerator equipped with a secondary multileaf collimator and universal wedge. J Appl Clin Med Phys 2002;3:302–9.
Mutic S, Klein EE. A reduction in the AAPM TG-36 reported peripheral dose distributions with tertiary multileaf collimation. Int J Radiat Oncol Biol Phys 1999;44:947–53.
Nisce LZ, Tome MA, He S, et al. Management of coexisting Hodgkin’s disease and pregnancy. Am J Clin Oncol 1986;9:146–51.
Nuytens JJ, Prado KL, Jenrette JM, et al. Fetal dose during radiotherapy: clinical implementation and review of the literature. Cancer Radiother 2002;6:352–7.
Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002;7:279–87.
Sharma DS, Animesh, Desphande SS, et al. Peripheral dose from uniform dynamic multileaf collimation fields: implications for sliding window intensity-modulated radiotherapy. Br J Radiol 2006;79:331–5.
Sherazi S, Kase KR. Measurements of dose from secondary radiation outside a treatment field: effects of wedges and blocks. Int J Radiat Oncol Biol Phys 1985;11:2171–6.
Stern RL. Peripheral dose from a linear accelerator equipped with multileaf collimation. Med Phys 1999;26:559–63.
Stovall M, Blackwell CR, Cundiff J, et al. Fetal dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task Group no. 36. Med Phys 1995;22:63–82.
Thomas PRM, Peckham MJ. The investigation and management of Hodgkin’s disease in the pregnant patient. Cancer 1976;38:1443–51.
Wiezorek T, Voigt A, Metzger N, et al. Experimental determination of peripheral doses for different IMRT techniques delivered by a Siemens linear accelerator. Strahlenther Onkol 2008;184:73–9.
Woo SY, Fuller LM, Cundiff JH, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1992;23:407–12.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mazonakis, M., Lyraraki, E., Varveris, C. et al. Conceptus dose from involved-field radiotherapy for Hodgkin's lymphoma on a linear accelerator equipped with MLCs. Strahlenther Onkol 185, 355–363 (2009). https://doi.org/10.1007/s00066-009-1932-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-009-1932-9